April 21st 2024
During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Expert Highlights Data that Led to the Approval of Fedratinib in Myelofibrosis
August 23rd 2019In an interview with <em>Targeted Oncology</em>, Ruben Mesa, MD, discussed the results from the reanalysis of the JAKARTA-2 trial that led to the approval of fedratinib in patients with MF. He also highlighted the role of the FREEDOM study that is currently enrolling patients with MF for treatment with fedratinib.
Read More
FDA Approves Fedratinib for the Treatment of Primary/Secondary Myelofibrosis
August 16th 2019The FDA has approved the treatment of fedratinib for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, including post-polycythemia vera or post-essential thrombocythemia myelofibrosis.
Read More
CPI-0610 Demonstrates Activity in Patients With Myelofibrosis After Ruxolitinib Failure
July 31st 2019Marina Kremyanskaya, MD, PhD, discusses unique findings from the phase II trial investigating the effect of CPI-0610, a bromodomain and extra-terminal protein inhibitor, as treatment for patients with myelofibrosis who previously progressed on ruxolitinib.
Watch
Tagraxofusp Appears Safe in Subgroup of Patients With Relapsed/Refractory Myelofibrosis
July 27th 2019In an interview with Targeted Oncology, Naveen Pemmaraju, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discussed the safety of SL-401 as a treatment in patients with MF following relapse or intolerance to JAK inhibition, based on data from an ongoing phase I/II clinical trial. He highlighted other research that also appear promising for this subgroup of patients with a poor prognosis.
Read More
Idasanutlin Clinically Active and Tolerable in PV, Phase I Trial Finds
July 24th 2019The MDM2 antagonist idasanutlin was found to be clinically active and well tolerated in patients with previously treated polycythemia vera. Additionally, on-target <em>TP53 </em>pathway activation was observed in treatment-refractory patients with PV who were treated with idasanutlin, according to the results of a phase I clinical trial.<br />
Read More
A Look Back at FDA News from June 2019
July 1st 2019In June 2019, the FDA approved a number of agents many fields, including diffuse large B-cell lymphoma, head and neck squamous cell carcinoma, small cell lung cancer, gastroenteropancreatic neuroendocrine tumors, and multiple myeloma. The FDA also approved the fifth biosimilar for trastuzumab and another biosimilar for bevacizumab across several indications.
Read More
New Agent Shows Synergy With JAK Inhibitor in Myelofibrosis After Ruxolitinib Failure
June 27th 2019In an interview with <em>Targeted Oncology, </em>Marina Kremyanskaya, MD, PhD, discussed the results from the phase II trial investigating the effects of CPI-0610 with or without ruxolitinib in patients with MF. Overall, the drug was well tolerated and effective in patients who had previously progressed on ruxolitinib or received inadequate responses to treatment.
Read More
Longer Duration of Hydroxyurea Treatment in PV Increases Incidence of MF, Mortality
June 21st 2019A new meta-analysis quantifying the risks and benefits of using hydroxyurea to treat polycythemia vera found that while the incidence of thrombosis and acute myeloid leukemia were stable over time, mortality and transformation to myelofibrosis varied depending on follow-up duration.
Read More
Polatuzumab Vedotin Combo Approved by FDA for R/R DLBCL
June 10th 2019Polatuzumab vedotin in combination with bendamustine and rituximab has been granted an accelerated approval from the FDA for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.<br />
Read More
FDA Grants Fast Track Designation to Momelotinib for Intermediate/High-Risk Myelofibrosis
June 6th 2019The FDA has granted a fast track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.<br />
Read More
Nazha Discusses Ongoing Trials for Ruxolitinib-Refractory Patients With Myelofibrosis
May 30th 2019Aziz Nazha, MD, discusses the different agents being explored for patients who have progressed on ruxolitinib, and why this is a significant unmet need. He also highlights the role of genetics in patients with MF and how a better understanding can help guide treatment decisions.
Read More
Komrokji Reviews the Advantages of JAK2 Inhibitors in a Case Study of a Patient With Myelofibrosis
May 24th 2019Rami S. Komrokji, MD, explains the diagnostic and molecular workup behind myeloproliferative neoplasm diagnoses and discusses treatment options based on the case scenario of a patient with myelofibrosis.
Read More
Examining the Link Between High-Risk Mutations and Transplant Outcomes in Myelofibrosis
May 23rd 2019Raajit K. Rampal, MD, PhD, discusses a retrospective analysis of pre-transplant samples from patients with MF to determine the value of mutational profiling in predicting outcomes after transplant.
Read More
A new report published in<em> Leukemia Research</em> found that results from the lead-in cohort of an open-label phase lb/II trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with at least 1 JAK inhibitor indicated acceptable safety and tolerability.
Read More